Tactile Systems Technology, Inc. announced on June 3, 2025, the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The data demonstrated significant clinical and quality-of-life benefits associated with the use of the company’s Flexitouch Plus system in treating lymphedema among head and neck cancer survivors.
The two-month analysis, derived from a six-month clinical trial, examined the effectiveness of Flexitouch Plus, an advanced pneumatic compression device (APCD), versus usual care. This study involved 236 subjects across 10 academic and community sites, making it the largest prospective, randomized controlled study on this patient group in the United States.
The results indicated that both usual care and APCD are similarly effective treatment modalities for head and neck lymphedema. Specific areas of differentiation showed that Flexitouch Plus provides an effective option that reduces swelling and increases the speed to initial therapy, addressing a critical need for patients where 90% of head and neck cancer survivors develop lymphedema.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.